IP Verse

Rapid Dissolution Formulation Of A Calcium Receptor-Active Compound

EP3578175

AMGEN
Application Number
EP19164145A
Filing Date
Sep 10, 2004
Status
Granted And Under Opposition
Oct 28, 2022
Grant Date
Nov 30, 2022
External Links
Slate, Register

Biblio Summary

The patent EP3578175B1 was granted on Nov 30, 2022 by Amgen The patent is currently Granted And Under Opposition.

Oppositions Filed by other Companies on the Patent

The table below shows 7 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BIOGARANAug 30, 2023ADMISSIBLE
GLENMARK PHARMACEUTICALS EUROPE LTDAug 30, 2023ADMISSIBLE
TAD PHARMA GMBHAug 30, 2023ADMISSIBLE
ARROW GENERIQUES / PUREN PHARMA GMBH & CO KGAug 29, 2023ADMISSIBLE
ELKINGTON AND FIFE LLPAug 29, 2023ADMISSIBLE
SANDOZAug 29, 2023ADMISSIBLE
HAMM&WITTKOPP PATENTANWALTE PARTMBBAug 24, 2023ADMISSIBLE

More Opposed Patents of Amgen

The table below shows the patents of Amgen that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP4209499Charged Depth Filtration Of Antigen-Binding ProteinsAug 7, 20241
EP3819007Dosing Regimen For Anti-Bcma AgentsJul 10, 20244
EP2637670Prevention Of Adverse Effects Caused By Cd3 Specific Binding DomainsMar 13, 20244

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.

  • Date

    Description

  • Get instant alerts for new documents